234 related articles for article (PubMed ID: 28174220)
1. Comparisons of neurodegeneration over time between healthy ageing and Alzheimer's disease cohorts via Bayesian inference.
Cespedes MI; Fripp J; McGree JM; Drovandi CC; Mengersen K; Doecke JD
BMJ Open; 2017 Feb; 7(2):e012174. PubMed ID: 28174220
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
3. Estimating individual trajectories of structural and cognitive decline in mild cognitive impairment for early prediction of progression to dementia of the Alzheimer's type.
Rajagopal SK; Beltz AM; Hampstead BM; Polk TA
Sci Rep; 2024 Jun; 14(1):12906. PubMed ID: 38839800
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Neuroimaging Hippocampal Markers for Diagnosing Alzheimer's Disease.
Platero C; Lin L; Tobar MC
Neuroinformatics; 2019 Jan; 17(1):43-61. PubMed ID: 29785624
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
7. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.
Chung JK; Plitman E; Nakajima S; Caravaggio F; Iwata Y; Gerretsen P; Kim J; Takeuchi H; Shinagawa S; Patel R; Chakravarty MM; Graff-Guerrero A;
J Alzheimers Dis; 2017; 58(3):747-762. PubMed ID: 28505977
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the performance of Bayesian and frequentist approaches for longitudinal modeling: application to Alzheimer's disease.
Pérez-Millan A; Contador J; Tudela R; Niñerola-Baizán A; Setoain X; Lladó A; Sánchez-Valle R; Sala-Llonch R
Sci Rep; 2022 Aug; 12(1):14448. PubMed ID: 36002550
[TBL] [Abstract][Full Text] [Related]
9. Test-retest reliability and longitudinal analysis of automated hippocampal subregion volumes in healthy ageing and Alzheimer's disease populations.
Worker A; Dima D; Combes A; Crum WR; Streffer J; Einstein S; Mehta MA; Barker GJ; Williams SCR; O'daly O
Hum Brain Mapp; 2018 Apr; 39(4):1743-1754. PubMed ID: 29341323
[TBL] [Abstract][Full Text] [Related]
10. Early Prediction of Alzheimer's Disease Using Null Longitudinal Model-Based Classifiers.
Gavidia-Bovadilla G; Kanaan-Izquierdo S; Mataró-Serrat M; Perera-Lluna A;
PLoS One; 2017; 12(1):e0168011. PubMed ID: 28045907
[TBL] [Abstract][Full Text] [Related]
11. The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease.
Tang X; Holland D; Dale AM; Younes L; Miller MI;
Hum Brain Mapp; 2015 Jun; 36(6):2093-117. PubMed ID: 25644981
[TBL] [Abstract][Full Text] [Related]
12. Neuro-degeneration profile of Alzheimer's patients: A brain morphometry study.
Ramos Bernardes da Silva Filho S; Oliveira Barbosa JH; Rondinoni C; Dos Santos AC; Garrido Salmon CE; da Costa Lima NK; Ferriolli E; Moriguti JC
Neuroimage Clin; 2017; 15():15-24. PubMed ID: 28459000
[TBL] [Abstract][Full Text] [Related]
13. Association Between Smoking and Cholinergic Basal Forebrain Volume in Healthy Aging and Prodromal and Dementia Stages of Alzheimer's Disease.
Teipel S; Grothe MJ;
J Alzheimers Dis; 2016 Apr; 52(4):1443-51. PubMed ID: 27079707
[TBL] [Abstract][Full Text] [Related]
14. Estimating anatomical trajectories with Bayesian mixed-effects modeling.
Ziegler G; Penny WD; Ridgway GR; Ourselin S; Friston KJ;
Neuroimage; 2015 Nov; 121():51-68. PubMed ID: 26190405
[TBL] [Abstract][Full Text] [Related]
15. Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
Cao L; Wang HF; Tan L; Sun FR; Tan MS; Tan CC; Jiang T; Yu JT; Tan L;
Oncotarget; 2016 Mar; 7(12):13319-27. PubMed ID: 26950278
[TBL] [Abstract][Full Text] [Related]
16. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
Lindemer ER; Salat DH; Smith EE; Nguyen K; Fischl B; Greve DN;
Neurobiol Aging; 2015 Sep; 36(9):2447-57. PubMed ID: 26095760
[TBL] [Abstract][Full Text] [Related]
17. Manual segmentation of the fornix, fimbria, and alveus on high-resolution 3T MRI: Application via fully-automated mapping of the human memory circuit white and grey matter in healthy and pathological aging.
Amaral RSC; Park MTM; Devenyi GA; Lynn V; Pipitone J; Winterburn J; Chavez S; Schira M; Lobaugh NJ; Voineskos AN; Pruessner JC; Chakravarty MM;
Neuroimage; 2018 Apr; 170():132-150. PubMed ID: 27765611
[TBL] [Abstract][Full Text] [Related]
18. Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease.
Cavedo E; Suppa P; Lange C; Opfer R; Lista S; Galluzzi S; Schwarz AJ; Spies L; Buchert R; Hampel H; ;
J Alzheimers Dis; 2017; 60(1):151-164. PubMed ID: 28777748
[TBL] [Abstract][Full Text] [Related]
19. Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling.
Cobigo Y; Goh MS; Wolf A; Staffaroni AM; Kornak J; Miller BL; Rabinovici GD; Seeley WW; Spina S; Boxer AL; Boeve BF; Wang L; Allegri R; Farlow M; Mori H; Perrin RJ; Kramer J; Rosen HJ;
Neuroimage Clin; 2022; 36():103144. PubMed ID: 36030718
[TBL] [Abstract][Full Text] [Related]
20. Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease.
Ofori E; DeKosky ST; Febo M; Colon-Perez L; Chakrabarty P; Duara R; Adjouadi M; Golde TE; Vaillancourt DE;
Neuroimage Clin; 2019; 24():101985. PubMed ID: 31470214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
